farnaz shokraneh | personalized medicine | Best Researcher Award

Posted on by ScienceFather

Ms. farnaz shokraneh | personalized medicine | Best Researcher Award

Abo Akademi University, Finland

👨‍🎓Professional Profile 

Orcid Profile

👩‍🔬 Summary

Ms. Farnaz Shokraneh is an experienced pharmaceutical professional currently working as a Doctoral Researcher in Pharmaceutical Development and Medical Technology at Ă…bo Akademi University in Turku, Finland. With a solid academic background and extensive practical experience in pharmaceutical quality assurance, regulatory compliance, and research, she brings valuable insights into the development of pharmaceutical products and systems. She is committed to advancing personalized medicine and improving quality control in the pharmaceutical industry.

🎓 Education

Ms. Shokraneh holds a Doctor of Pharmacy degree, equivalent to a Finnish Master’s, from Islamic Azad University, Tehran, Iran (2007-2012). She furthered her academic journey with a Master’s in Pharmaceutical Research from Freie Universität Berlin, Germany (2022-2024). Currently, she is pursuing her doctoral research in Pharmaceutical Development and Medical Technology at Åbo Akademi University, Turku, Finland (2022–present).

đź’Ľ Professional Experience

Ms. Shokraneh has accumulated extensive experience in various roles within the pharmaceutical industry. She is currently serving as a Quality Manager at CurifyLabs Oy in Helsinki, Finland, since September 2022. Previously, she held the position of Quality Assurance Manager at Mofid Pharma under the license of Bayer Pharmaceutical Company (Dec 2020–Dec 2021). Additionally, she has worked at Modava Pharmaceutical under Novartis (Jul 2018–Jul 2020) and ATI Pharmed Pharmaceutical Co under StragenPharma and CHEMO Pharmaceutical licenses (Apr 2013–Jun 2017).

🛠️ Technical Skills

Ms. Shokraneh’s technical expertise encompasses pharmaceutical development, quality assurance, and regulatory compliance. She is proficient in analytical techniques such as HPLC, mass spectrometry, and micro NIR spectrophotometry. Her experience also extends to pharmacovigilance, safety monitoring, and statistical analysis for pharmaceutical applications, making her highly skilled in ensuring the safety, efficacy, and quality of pharmaceutical products.

🧑‍🏫 Teaching Experience

Although Ms. Shokraneh’s current focus is on research and industry roles, her vast knowledge and experience in the pharmaceutical field allow her to effectively mentor teams and share her expertise. She has contributed to the professional development of her colleagues and participated in educational training programs within the pharmaceutical sector.

🔬 Research Interests

Ms. Shokraneh’s primary research interests lie in pharmaceutical development and medical technology, with a particular focus on personalized medicine. She is passionate about improving drug safety and efficacy through innovations in automated pharmacy compounding, quality control, and exploring new methods for drug delivery and patient-specific treatment plans.

 

đź“–Top Noted Publications

Automated Non-Sterile Pharmacy Compounding: A Multi-Site Study in European Hospital and Community Pharmacies with Pediatric Immediate Release Propranolol Hydrochloride Tablets

Authors: Niklas Sandler Topelius, Farnaz Shokraneh, Mahsa Bahman, Julius Lahtinen, Niko Hassinen, Sari Airaksinen, Soumya Verma, Ludmila Hrizanovska, Jana Lass, Urve Paaver et al.

Journal: Pharmaceutics

Year: 2024

A Novel High Performance Liquid Chromatographic Method for Determination of Nystatin in Pharmaceutical Formulations by Box–Behnken Statistical Experiment Design

Authors: Farnaz Shokraneh

Journal: Iranian Journal of Pharmaceutical Research

Year: 2014

Comparative Studies of Cytotoxic Manufacturing Practices in Specialized Cancer Centers Against International Guidelines (ASHP, OSHA, HSE-UK)

Authors: Farnaz Shokraneh

Journal: FIP Congress

Year: 2012

Development and Validation of High-Performance Liquid Chromatography for Determination of Nystatin in Pharmaceutical Formulations

Authors: Farnaz Shokraneh

Journal: Research in Pharmaceutical Science

Year: 2012

A New HPLC Method for Determination of Losartan in Human Plasma and Its Application in Bioequivalence Studies

Authors: Farnaz Shokraneh

Journal: Oriental Journal of Chemistry

Year: 2012

Risks to Health Professionals from Hazardous Drugs in Iran: A Pilot Study of Understanding of Healthcare Team to Occupational Exposure to Cytotoxics

Authors: Farnaz Shokraneh

Journal: EXCLI Journal

Year: 2005

Laurence Vaughan | Medical Diagnostics | Best Researcher Award

Posted on by ScienceFather

Dr. Laurence Vaughan | Medical Diagnostics | Best Researcher Award

Dr. Laurence Vaughan at Becton Dickinson and Company, United States

👨‍🎓 Professional Profile

🎓 Early Academic Pursuits

Dr. Laurence Vaughan began his academic journey at the University of Dublin, Trinity College, where he earned a BA (Honors) in Natural Sciences (Genetics) in 1986, followed by a Ph.D. in Molecular Microbiology in 1991. His doctoral research focused on the aroA gene of Aeromonas salmonicida, contributing to foundational knowledge in microbiology and vaccine development.

🏢 Professional Endeavors

Dr. Vaughan’s career spans over three decades in the biotechnology and molecular diagnostics sectors. Currently, he serves as the Director of Scientific Affairs at Becton Dickinson and Company, focusing on integrated diagnostic solutions for women’s health, particularly cervical cancer screening. His past roles include R&D leadership at QIAGEN and Corning Incorporated, where he made significant advancements in molecular assay development and product support.

🌟 Contributions and Research Focus

Dr. Vaughan has led teams in developing groundbreaking products such as the BD Onclarity cervical cancer screening test, which received CE Mark approval in 2014 and US-PMA approval in 2018. He has authored content for international conferences and peer-reviewed publications, emphasizing his commitment to advancing scientific knowledge and product innovation in the diagnostics field.

🌍 Impact and Influence

His work has not only shaped diagnostic guidelines but has also influenced industry standards, as seen with the American Society for Colposcopy and Cervical Pathology (ASCCP) management guidelines launched in 2020. Dr. Vaughan’s expertise is recognized internationally, making him a sought-after speaker at various conferences.

đź“š Academic Cites

Dr. Vaughan has made notable contributions to the field of vaccinology, evidenced by multiple patents and publications. His editorial experience as the Editor-in-Chief of “Diseases of Aquatic Organisms” from 1995 to 1999 further underscores his leadership in academic discourse.

🔧 Technical Skills

Dr. Vaughan possesses extensive technical skills in molecular biology, microbiology, and genetics. His proficiency in managing clinical trials, particularly in the R&D lead for Onclarity HPV clinical trials, highlights his ability to oversee complex scientific projects.

👩‍🏫 Teaching Experience

Throughout his career, Dr. Vaughan has demonstrated a passion for education and mentorship. He has developed and delivered training for global customers and internal teams, showcasing his strong communication and interpersonal skills.

🏅 Legacy and Future Contributions

Dr. Vaughan’s legacy includes a robust portfolio of innovations and leadership in the biotech field. His achievements, such as the Becton Dickinson Wesley J. Howe Award for Technological Innovation in 2013, reflect his dedication to advancing science and technology. Looking ahead, he aims to continue contributing to the development of effective diagnostic solutions and vaccines, focusing on emerging health challenges.

 

đź“– Top Noted Publications

Variables that impact HPV test accuracy during vaginal self collection workflow for cervical cancer screening

Authors: Vaughan, L., Gary, D., Shah, M., Galbraith, L., Parvu, V.
Journal: Gynecologic Oncology Reports
Year: 2024

Risk stratification of HPV-positive results using extended genotyping and cytology: Data from the baseline phase of the Onclarity trial

Authors: Stoler, M.H., Parvu, V., Yanson, K., Andrews, J., Vaughan, L.
Journal: Gynecologic Oncology
Year: 2023

Validation of a New High-Throughput BD COR System Using the BD CTGCTV2 Assay

Authors: Taylor, S., Rucki, A., Lockamy, E., Vaughan, L., Greene, W.
Journal: Journal of Molecular Diagnostics
Year: 2022

Evaluation of the Onclarity HPV assay on the high-throughput COR system

Authors: Taylor, S.N., Eckert, K., Rucki, A.A., Vaughan, L.M., Greene, W.H.
Journal: Expert Review of Molecular Diagnostics
Year: 2021

Cotesting in cervical cancer screening

Authors: Malinowski, D.P., Broache, M., Vaughan, L., Andrews, J., Gary, D.
Journal: American Journal of Clinical Pathology
Year: 2021

Analytical and clinical sample performance characteristics of the onclarity assay for the detection of human papillomavirus

Authors: Young, S., Vaughan, L., Yanson, K., Cooper, C.K., van der Pol, B.
Journal: Journal of Clinical Microbiology
Year: 2021